Insignia

    A Sirolimus Drug Eluting System

    Insignia Sirolimus Drug Eluting System Elutes Sirolimus Biodegradable Polymer Matrix. The Drug is coated on the both Albuminal and Luminal Surfaces of the stent and is released in a controlled manner. This Gives the Device the Superior Safety and Efficacy

    Best in Class Stent and Stent Delivery System
    • Material – L605 Cobalt Chromium
    • Stent Geometry – Hybrid Cell
    • Low Strut Thickness – 73 Microns
    • Low Balloon overhang to reduce the injury
    • Low Crossing and Tip entry profile with hydrophilic coating
    • Chemical Treatment for excellent surface finish
    • Smooth surface
    • Supports easy stent implantation
    Biodegradable Polymers
    • Blend of PLA and PLGA polymer with high Purity (>99.99%)
    • Fully Biodegradable and Biocompatible polymers
    • The Lactate produce after degradation of polymer blend will increase the VEGF and VEGF further promotes the endothelial cell growth
    • The uniform circumferential coating of drug & polymer on the stent with a unique spray coating technology maintains its integrity in vitro tortuous path
    Drug Sirolimus
    • LOADING DOSE:- 4 micro gram /Sq mm
    • Sirolimus as mTOR inhibitor, Inhibits Smooth Muscle Cell Proliferation and migration by suppression of m-TOR mediated 56K1 and 4E-BP1 pathways
    • Sirolimus eluting stents ranges between 34 micrograms to 412 micrograms
    • Stability: Sirolimus is increased by creating an inert atmosphere in the packaging process

    Drug Release Kinetics

    Programmed controlled release kinetics and release pattern. The initial burst release of Sirolimus on day 1 with 20% of the loading dose inhibits the smooth-muscle cell proliferation and rest of the Sirolimus further released from the stent inhibits both proliferation and migration of the SMC (90% of drug releases in 6 weeks)

    Stent Apposition

    Excellent Stent Apposition as evidenced in OCT with a score of less than 20 Microns

    Brochure Insignia